Repligen to Acquire BioLife Solutions in Mixed-Consideration Merger Valued at $11.25 Cash Plus Stock Per Share

Transaction Structure and Merger Framework

The acquisition will be executed through a two-step merger process involving two wholly owned subsidiaries of Repligen. In the first merger, Bravo Merger Sub I, Inc., a Delaware corporation and direct subsidiary of Repligen, will merge with and into BioLife Solutions, with BioLife surviving as a direct wholly owned subsidiary of Repligen. Immediately following the first merger, BioLife will merge with Bravo Merger Sub II, LLC, with Merger Sub II surviving as a direct wholly owned subsidiary of Repligen. This structure is commonly used in merger transactions to facilitate the integration of the acquired company while maintaining certain operational continuities during the transition period.

The boards of directors of both Repligen and BioLife have approved the Merger Agreement and the transactions contemplated thereby. The disclosure indicates that each party made customary representations, warranties, and covenants in the Merger Agreement, with both companies agreeing to conduct their respective businesses in the ordinary course consistent with past practice during the period between execution and closing. Both Repligen and BioLife committed to use reasonable best efforts to satisfy the closing conditions and to preserve substantially their present business organizations and material assets during the interim period.

Cash and Stock Consideration Breakdown

BioLife shareholders will receive hybrid consideration consisting of both cash and equity. The cash component is fixed at $11.25 per share, paid without interest. The stock component is determined by an exchange ratio of 0.1442 shares of Repligen common stock for each share of BioLife Common Stock outstanding at the effective time of the first merger. This mixed consideration structure allows BioLife shareholders to receive both liquidity and continued equity participation in the combined entity through Repligen shares.

The Merger Agreement specifies that no fractional shares of Repligen common stock will be issued as part of the transaction. Instead, BioLife shareholders who would otherwise receive fractional shares will receive cash in lieu of those fractional shares, as detailed in the Merger Agreement. This provision ensures that the transaction settlement process is administratively feasible while providing full compensation to all shareholders participating in the merger.

Acceleration and Settlement of BioLife Equity Awards

The Merger Agreement includes provisions governing the treatment of outstanding BioLife equity awards upon closing. All BioLife Options—whether vested or unvested—will become fully vested immediately prior to the first merger effective time. These options will be cancelled in exchange for a net-settled payment to the holder in shares of BioLife Common Stock calculated as the intrinsic value of the options, after deducting applicable withholding taxes.

Time-based restricted stock units, or BioLife RSUs, will accelerate vesting in full and be settled in shares of BioLife Common Stock. Performance-based restricted stock units, or BioLife PSUs, will also accelerate vesting in full and be settled by assuming the greater of target or actual achievement of the applicable performance goals as measured as of the latest practicable date prior to the first merger effective time. Outstanding unvested restricted stock awards, or BioLife RSAs, will accelerate vesting in full and be released to the holder. All shares of BioLife Common Stock issuable pursuant to these awards will then be converted automatically into the right to receive the Merger Consideration as of the first merger effective time, ensuring that BioLife employees and equity holders receive the full benefit of their awards through the merger consideration.

Stockholder Approval and Regulatory Requirements

Consummation of the mergers is conditional upon approval by the holders of a majority of the outstanding shares of BioLife Common Stock entitled to vote at a duly held stockholders' meeting. This BioLife Stockholder Approval represents a fundamental condition to closing. Additionally, the shares of Repligen common stock to be issued in the first merger must be approved for listing on The Nasdaq Stock Market, ensuring that Repligen's issuance of shares in the transaction complies with Nasdaq listing standards.

The transaction is also subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the receipt of consents required under antitrust laws of specified jurisdictions. The Securities and Exchange Commission must declare effective a Registration Statement on Form S-4 to be filed by Repligen, which will contain the proxy statement and prospectus for the parties in connection with the mergers. The immediate share price impact was not clear from available public information at the time of the filing.

Representation, Warranties, and Covenants

Both Repligen and BioLife have made customary representations and warranties in the Merger Agreement covering standard transaction elements. These representations address matters such as organization, capitalization, authority, and absence of undisclosed liabilities. The disclosure does not provide a detailed enumeration of all representations and warranties, but indicates that each party has represented the accuracy of its financial condition, business operations, and legal standing.

The parties have also committed to customary covenants governing their conduct during the interim period. BioLife has agreed to use reasonable efforts to conduct its business in the ordinary course consistent with past practice, with specified exceptions subject to Repligen's written consent. Similarly, Repligen has agreed to use reasonable efforts to conduct its business in the ordinary course consistent with past practice, with specified exceptions subject to BioLife's written consent. These interim operating covenants are designed to preserve the value and operations of each company until closing.

Closing Conditions and Material Adverse Effect Provision

The consummation of the mergers is subject to the absence of any adverse law or order that restrains, enjoins, makes illegal, or otherwise prohibits the consummation of the mergers. The Merger Agreement also conditions closing on the absence of a continuing material adverse effect with respect to each of Repligen and BioLife. The disclosure indicates that certain materiality exceptions apply to the accuracy of representations and warranties and compliance with covenants, though the specific exceptions are not detailed in the filing excerpt provided.

The parties anticipate that the mergers will be completed in the fourth quarter of 2026, subject to satisfaction of these customary closing conditions. The timeline reflects the need to complete regulatory filings, obtain stockholder approval, and satisfy antitrust review requirements. The exact closing date will depend on the timing of these various approvals and the absence of intervening circumstances that would delay or prevent consummation of the transaction.

Business Operations and Integration Expectations

Repligen Corporation is a life sciences company with established capabilities in bioprocessing and laboratory automation technology. The company serves biopharmaceutical manufacturers and research organizations. BioLife Solutions, Inc., operates in the biotech sector with a focus on biopreservation solutions and technologies. The disclosure does not provide detailed financial metrics or revenue figures for either company, and such information would typically appear in periodic reports or prospectus documents rather than in the merger announcement itself.

The transaction represents a strategic combination of complementary capabilities in the life sciences and biotech sectors. The interim covenants requiring both companies to maintain ordinary course operations suggest that management intends to preserve the operational integrity of both businesses through closing. Investors should monitor subsequent disclosures, including the Form S-4 registration statement, for additional details regarding the combined company's business strategy and financial projections.

Outstanding Questions and Investor Considerations

The company did not disclose financial metrics such as the total transaction value, the relative sizes of the two companies by revenue or market capitalization, or details regarding the combined entity's expected financial performance. These figures will likely be included in the Form S-4 registration statement that Repligen will file with the Securities and Exchange Commission. Investors should review that document for comprehensive financial analysis and management's discussion of synergies and integration plans.

The disclosure also does not specify the expected timing of individual regulatory approvals, such as Hart-Scott-Rodino clearance or Nasdaq listing approval. Delays in any of these approvals could impact the expected fourth quarter 2026 closing timeline. Investors should monitor future announcements for updates on the progress of regulatory filings and approvals. The Merger Agreement includes customary termination rights and termination fee provisions, though the specific details are not included in this announcement.